A number of other equities research analysts have also recently weighed in on the company. Berenberg Bank set a €47.00 ($49.47) price target on Evotec in a report on Wednesday, April 20th. Jefferies Financial Group set a €55.00 ($57.89) price target on Evotec in a research note on Wednesday, March 2nd. Deutsche Bank Rese… set a €33.00 ($34.74) price objective on shares of Evotec in a research note on Tuesday, April 19th. Morgan Stanley set a €42.00 ($44.21) target price on shares of Evotec in a report on Friday, April 29th. Finally, Royal Bank of Canada set a €43.00 ($45.26) price target on shares of Evotec in a report on Tuesday.
Shares of EVT opened at €24.14 ($25.41) on Wednesday. Evotec has a twelve month low of €20.24 ($21.31) and a twelve month high of €45.83 ($48.24). The company has a current ratio of 3.39, a quick ratio of 3.19 and a debt-to-equity ratio of 37.23. The firm has a market capitalization of $4.27 billion and a P/E ratio of 16.53. The firm’s 50-day moving average is €25.53 and its two-hundred day moving average is €33.06.
Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health.
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.